<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Sparsentan</id>
	<title>Sparsentan - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Sparsentan"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Sparsentan&amp;action=history"/>
	<updated>2026-04-25T23:55:10Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Sparsentan&amp;diff=4963552&amp;oldid=prev</id>
		<title>Deepika vegiraju at 12:04, 11 June 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Sparsentan&amp;diff=4963552&amp;oldid=prev"/>
		<updated>2023-06-11T12:04:08Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== &amp;#039;&amp;#039;&amp;#039;What is Sparsentan?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
 &lt;br /&gt;
* Sparsentan (&amp;#039;&amp;#039;&amp;#039;Filspari&amp;#039;&amp;#039;&amp;#039;) is &amp;#039;&amp;#039;&amp;#039;an endothelin and angiotensin II receptor antagonist&amp;#039;&amp;#039;&amp;#039;. &lt;br /&gt;
&lt;br /&gt;
[[File:Sparsentan.svg|thumb|Sparsentan]]&lt;br /&gt;
&lt;br /&gt;
[[File:Sparsentan 02.svg|thumb|Sparsentan 02]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;youtube&amp;gt;&lt;br /&gt;
title=&amp;#039;&amp;#039;&amp;#039;{{PAGENAME}}&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
movie_url=http://www.youtube.com/v/v=KH826qSwLs8&lt;br /&gt;
embed_source_url=http://www.youtube.com/v/v=KH826qSwLs8&lt;br /&gt;
&amp;amp;rel=1&lt;br /&gt;
wrap = yes&lt;br /&gt;
width=750&lt;br /&gt;
height=600&lt;br /&gt;
&amp;lt;/youtube&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the uses of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Sparsentan (&amp;#039;&amp;#039;&amp;#039;Filspari&amp;#039;&amp;#039;&amp;#039;) is a prescription medicine used to reduce levels of protein in the urine ([[proteinuria]]) in adults with a kidney disease called primary immunoglobulin A nephropathy ([[IgAN]]), who are at risk of their disease progressing quickly.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How does this medicine work?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Sparsentan is a single molecule wit&amp;#039;&amp;#039;&amp;#039;h antagonism of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R)&amp;#039;&amp;#039;&amp;#039;. &lt;br /&gt;
* Sparsentan has &amp;#039;&amp;#039;&amp;#039;high affinity for both the ETAR and the AT1R&amp;#039;&amp;#039;&amp;#039;, and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. &lt;br /&gt;
* Endothelin-1 and angiotensin II are thought to contribute to the pathogenesis of [[IgAN]] via the ETAR and AT1R, respectively.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Who Should Not Use this medicine ?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine cannot be used in patients who:&lt;br /&gt;
* are pregnant, plan to become pregnant, or become pregnant during treatment with Filspari. &lt;br /&gt;
* are taking any of these medicines:&lt;br /&gt;
* an [[angiotensin receptor blocker]], or&lt;br /&gt;
* an [[endothelin receptor antagonist]], or&lt;br /&gt;
* [[aliskiren]]&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What drug interactions can this medicine cause?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and [[grapefruit]] you are taking or plan to take.&lt;br /&gt;
* Filspari and other medicines may affect each other and cause side effects. Do not start any new medicine until you check with your healthcare provider.&lt;br /&gt;
&lt;br /&gt;
Be sure to mention any of the following:&lt;br /&gt;
* [[nonsteroidal anti-inflammatory drugs]] (NSAIDs)&lt;br /&gt;
* [[potassium]]-containing medicines, potassium supplements or salt substitutes containing potassium&lt;br /&gt;
* blood pressure medicines&lt;br /&gt;
* Acid reducing agents&lt;br /&gt;
* [[Antacids]]: Avoid use within 2 hours before or after use of sparsentan. May decrease exposure to sparsentan.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Is this medicine FDA approved?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* It was approved for medical use in the United States in February 2023.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How should this medicine be used?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Prior to initiating treatment with Filspari, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs), and [[aliskiren]].&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Recommended dosage:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Initiate treatment with Filspari at &amp;#039;&amp;#039;&amp;#039;200 mg orally once daily&amp;#039;&amp;#039;&amp;#039;. &lt;br /&gt;
* After 14 days, increase to the recommended dose of &amp;#039;&amp;#039;&amp;#039;400 mg once daily&amp;#039;&amp;#039;&amp;#039;, as tolerated. &lt;br /&gt;
* When resuming treatment with Filspari after an interruption, consider titration of Filspari, starting at 200 mg once daily. &lt;br /&gt;
* After 14 days, increase to the recommended dose of 400 mg once daily.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Administration:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Take Filspari exactly as your healthcare provider tells you to take it. &lt;br /&gt;
* Do not stop taking Filspari unless your healthcare provider tells you.&lt;br /&gt;
* Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Filspari if you develop side effects.&lt;br /&gt;
* Swallow Filspari whole with water before your morning or evening meal. &lt;br /&gt;
* Take your dose with the same meal each day.&lt;br /&gt;
* If you miss a dose, take the next dose at the regularly scheduled time. &lt;br /&gt;
* Do not take 2 doses at the same time or take extra doses.&lt;br /&gt;
* Talk to your healthcare provider before using antacid medicines because they may affect how Filspari works.&lt;br /&gt;
* If you take too much Filspari, call your healthcare provider or go to the nearest hospital emergency room right away.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the  dosage forms and brand names of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing doasage form:&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;As Tablets:&amp;#039;&amp;#039;&amp;#039; 200 mg and 400 mg &lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing brand namesː&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Filspari&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;What side effects can this medication cause?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
The most common side effects of this medicine may include:&lt;br /&gt;
* swelling of hands, legs, ankles and feet ([[peripheral edema]])&lt;br /&gt;
* [[dizziness]]&lt;br /&gt;
* low red blood cells ([[anemia]])&lt;br /&gt;
&lt;br /&gt;
Less common, but serious side effects may include:&lt;br /&gt;
* Liver problems&lt;br /&gt;
* Serious birth defects&lt;br /&gt;
* Low blood pressure&lt;br /&gt;
* Worsening of Kidney function&lt;br /&gt;
* Increased [[potassium]] in your blood&lt;br /&gt;
* Fluid retention&lt;br /&gt;
* serious birth defects if taken during pregnancy.&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039; What special precautions should I follow?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Elevations in ALT or AST of at least 3-fold ULN have been observed in Filspari-treated patients. Advise patients with symptoms suggesting [[hepatotoxicity]] (nausea, vomiting, right upper quadrant pain, [[fatigue]], [[anorexia]], [[jaundice]], dark urine, fever, or itching) to immediately stop treatment with Filspari and seek medical attention . &lt;br /&gt;
* Based on data from animal reproduction studies, Filspari can cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with Filspari, monthly during treatment and one month after discontinuation of treatment. Advise patients who can become pregnant to use effective [[contraception]] prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with Filspari.&lt;br /&gt;
* [[Hypotension]] has been observed in patients treated with ARBs and [[Endothelin receptor antagonist|endothelin receptor antagonists]](ERAs) and was observed in clinical studies with Filspari. If hypotension develops, despite elimination or reduction of other antihypertensive medications, consider a dose reduction or dose interruption of Filspari. &lt;br /&gt;
* Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system can cause [[acute kidney injury]]. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on Filspari.&lt;br /&gt;
* Monitor serum [[potassium ]]periodically and treat appropriately. Patients with advanced kidney disease or taking concomitant potassium-increasing drugs (e.g., potassium supplements, [[potassium-sparing diuretics]]), or using potassium-containing salt substitutes are at increased risk for developing [[hyperkalemia]]. Dosage reduction or discontinuation of Filspari may be required.&lt;br /&gt;
* [[Fluid retention]] may occur with endothelin receptor antagonists and has been observed in clinical studies with Filspari. Filspari has not been evaluated in patients with [[heart failure]].&lt;br /&gt;
* Advise patients not to use potassium supplements or salt substitutes that contain potassium without consulting their healthcare provider.&lt;br /&gt;
* Advise patients to take the full daily dose with water prior to the morning or evening meal. Maintain the same dosing pattern in relationship to meals. If a dose is missed, take the next dose at the regularly scheduled time. Do not take double or extra doses.&lt;br /&gt;
* Advise patients not to breastfeed during treatment with Filspari.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What to do in case of emergency/overdose?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
Symptoms of overdosage may include:&lt;br /&gt;
* decreased [[blood pressure]]&lt;br /&gt;
&lt;br /&gt;
Management of overdosage:&lt;br /&gt;
* {{overdose}}&lt;br /&gt;
* In the event of an overdose, standard supportive measures should be taken, as required. &lt;br /&gt;
* [[Dialysis]] is unlikely to be effective because sparsentan is highly protein-bound.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Can this medicine be used in pregnancy?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Based on data from animal reproductive toxicity studies, Filspari can cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy.&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;Can this medicine be used in children?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
* The safety and efficacy of Filspari in pediatric patients have not been established.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the active and inactive ingredients in this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Active ingredient:&amp;#039;&amp;#039;&amp;#039; sparsentan&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Inactive ingredients:&amp;#039;&amp;#039;&amp;#039; colloidal silicon dioxide, lactose anhydrous, magnesium stearate, silicified microcrystalline cellulose, and sodium starch glycolate. Tablets are film coated with material containing macrogol/polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Who manufactures and distributes this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
Distributed by: &lt;br /&gt;
* [[Travere Therapeutics, Inc.]], San Diego, CA&lt;br /&gt;
* Filspari is a registered trademark of Travere Therapeutics, Inc.&lt;br /&gt;
                                                          &lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What should I know about storage and disposal of this medication?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Store Filspari at room temperature between 68°F to 77°F (20°C to 25°C).&lt;br /&gt;
* Store Filspari in the original container.&lt;br /&gt;
* The bottle has a child-resistant closure.&lt;br /&gt;
&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{Portal bar | Medicine}}&lt;br /&gt;
[[Category:Orphan drugs]]&lt;br /&gt;
{{Pharma-stub}}&lt;/div&gt;</summary>
		<author><name>Deepika vegiraju</name></author>
	</entry>
</feed>